Abstract:Introduction: Nasopharyngeal carcinoma (NPC) originates from the mucous epithelium of the nasopharynx. Although induction chemotherapy plus concurrent chemoradiotherapy is the major therapeutic protocol used for locally advanced NPC without metastasis, more research studies are needed to evaluate the curative effects. We aim to identify the therapeutic effects and prognosis after induction chemotherapy plus concurrent chemoradiotherapy in the treatment of locally advanced NPC under the intensity-modulated radiotherapy mode. Methods: The patients ( N = 544) with locally advanced NPC (III and Iva, UICC 8th) after intensity-modulated radiotherapy with induction chemotherapy and concurrent chemoradiotherapy were included in this study. We analyzed the characteristics of patients including gender, age, smoking status, tumor node staging system, clinical stage, pathological type, the therapy protocol of induction chemotherapy and concurrent chemoradiotherapy, and chemotherapy prescription. Results: We have found the 5-year survival rates of overall survival (OS), progression-free survival (PFS), locoregional relapse-free survival (LRRFS), and distant metastasis-free survival (DMFS) were 85.21%, 78.51%, 90.71%, and 85.21% in follow-up, and these data indicated that our therapeutic procedure provided beneficial effects on survival rates. Subsequently, the chemotherapy drug based on docetaxel (DOC) provided a more beneficial effect on survival rate compared with taxol (TXT) (all estimated HR >1; p = 0.005, 0.004, and <0.001 of OS, PFS, and DMFS), but there was no significant difference between chemotherapy drugs based on cisplatin (DDP) and nedaplatin (NDP) in treating NPC patients ( p = 0.390, 0.549, 0.364, and 0.645 of OS, PFS, LRRFS, and DMFS). The therapeutic effects of induction chemotherapy revealed no difference between TPF and TP (T: DOC or TXT, P: DDP or NDP, and F: 5-fluorouracil) ( p = 0.541, 0.897, 0.498, and 0.765 of OS, PFS, LRRFS, and DMFS). In addition, there was also no significant change between concurrent chemotherapy with TP dual drugs or a single platinum drug (being excluded in the multivariate model using forward [Wald] procedure). Moreover, the survival rate showed no difference between platinum accumulation dose of more or less than 150 mg/m 2 for concurrent chemotherapy (being excluded in the multivariate model using forward [Wald] procedure). Conclusion: Our results indicate that induction chemotherapy plus concurrent chemoradiotherapy under intensity-modulated radiotherapy which is the standard therapeutic method for locally advanced NPC provides beneficial therapeutic effects, and it is worthy of further study.

A Study of the Combined Treatment Strategy for Patients with Nasopharyngeal Carcinoma Based on the Analysis of the Treatment Results from 749 Cases

Treatment result of radiotherapy alone for patients with early stage nasopharyngeal carcinoma

Role of intensity-modulated radiation therapy combined with chemotherapy in patients with stage T 1-2N 1M 0 nasopharyngeal carcinoma: a retrospective study

Clinical Analysis of Combined Therapy for Stage Ⅲ、Ⅳ Nasopharyngeal Carcinoma

Treatment results of nasopharyngeal carcinoma : a retrospective analysis of 1837 cases in a single institute

Evaluation of the prognostic factors of tumor staging for nasopharyngeal carcinoma

Systemic Chemotherapy and Sequential Locoregional Radiotherapy in Initially Metastatic Nasopharyngeal Carcinoma: Retrospective Analysis with 821 Cases

Can Neoadjuvant Chemotherapy Improve Survival in Stage T3-4N1 Nasopharyngeal Carcinoma? A Propensity Matched Analysis.

Multimodality Treatment May Improve The Survival Rate Of Patients With Metastatic Nasopharyngeal Carcinoma With Good Performance Status

Retrospective Analysis of Induction Chemotherapy plus Concurrent Chemoradiotherapy under Intensity-Modulated Radiotherapy Mode for Locally Advanced Nasopharyngeal Carcinoma

The efficacy of induction chemotherapy or adjuvant chemotherapy added to concurrent chemoradiotherapy in T3-4N0-1M0 nasopharyngeal carcinoma: a propensity score-matched analysis

Neoadjuvant Chemotherapy And Prognostic Subgroups Defined By Survival Benefit In Patients With Locoregionally Advanced Nasopharyngeal Carcinoma.

IMRT Combined with Concurrent Chemotherapy Plus Adjuvant Chemotherapy Versus IMRT Combined with Concurrent Chemotherapy Alone in Patients with Nasopharyngeal Carcinoma

Concurrent chemoradiotherapy versus radiotherapy alone for T3-4N0-1M0 and T1-4N2-3M0 nasopharyngeal carcinoma after induction chemotherapy

1108OChemotherapy plus local-regional radiotherapy versus chemotherapy alone in primary metastatic nasopharyngeal carcinoma: A randomized, open-label, phase III trial

Clinical Study of Concurrent Chemoradiotherapy for Patients with Locoregionally Advanced Nasopharyngeal Carcinoma

Retrospective Analysis of 234 Nasopharyngeal Carcinoma Patients with Distant Metastasis at Initial Diagnosis: Therapeutic Approaches and Prognostic Factors

Induction Chemotherapy Followed by Intensity-Modulated Radiotherapy Versus Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma: A Retrospective Analysis

Long-term results of concurrent chemoradiotherapy for T3/T4 locally advanced nasopharyngeal carcinoma.

Long-term outcomes of patients with advanced N-stage nasopharyngeal carcinoma treated by intensity-modulated radiotherapy alone or with chemotherapy

Survival impacts of different nodal characteristics and T-classification in N3 nasopharyngeal carcinoma patients